Weimei Gene raises $4.5M Pre-A to fund AAV gene therapy pipeline
What's the deal? Shanghai Weimei Gene TechnologyDealroom has a profile for this one. Try Dealroom → has raised US$4.13M in an early-stage Pre-A round. The deal was backed by Pudong Venture CapitalDealroom has a profile for this one. Try Dealroom →, through its Mingzhu Talent Fund.
What does it do? Founded in September 2021 and based in Shanghai's Zhangjiang biopharma cluster, Weimei develops gene therapies built on adeno-associated virus (AAV) vectors. It has created AAV-ie, a vector that targets hair cells and supporting cells, aimed at treating hereditary hearing disorders.
What's the money for? The funds will go toward preclinical research on its core pipeline and moving candidates toward the clinic, plus hiring and team expansion. Weimei holds proprietary AAV vectors with applications across ophthalmology and otology.
Why now? This is Weimei's latest raise in a steady string of deals. The company closed tens of millions of yuan in strategic funding in 2023, after an earlier angel round, keeping its early research funded step by step.
What could go wrong? One candidate, EA001, won US Food and Drug Administration orphan drug status in 2026. That designation is not proof of efficacy or a marketing approval — Weimei still has to show its vectors are safe and that the therapy works.
The signal: China's regulators have moved to speed up reviews of cell and gene therapies, lifting policy attention on the sector. The global gene therapy market was worth about $8.27 billion in 2023 and is projected to reach $25.01 billion by 2030, per Grand View Research. Weimei's round is a funding relay for early rare-disease research, not a sign of a product nearing the market.
Read more: itjuzi.com
Image credit: Generated with Gemini
